Integrative Group Program for Type 2 Diabetes Mellitus (T2DM)
Launched by TECSALUD INVESTIGACIÓN CLÍNICA · May 25, 2023
Trial Information
Current as of June 09, 2025
Recruiting
Keywords
ClinConnect Summary
**Summary of the Integrative Group Program for Type 2 Diabetes Mellitus Clinical Trial**
This clinical trial is looking at how a special group program can help people with Type 2 Diabetes manage their health better and feel better overall. The program includes six in-person sessions led by a health coach, happening every other week, along with six online sessions over a 12-week period. The goal is to see if this combined approach improves blood sugar control and enhances the participants' sense of well-being.
To be part of this trial, participants should be between 18 and 80 years old, have been diagnosed with Type 2 Diabetes within the last five years, and live in Nuevo León, Mexico. They must also be able to read and write and provide written consent to join. Unfortunately, those currently using insulin, diagnosed with diabetes for over five years, or with certain health conditions (like active cancer or severe mental illness) cannot participate. Participants in the trial can expect to engage in both group discussions and online learning, all designed to support their journey in managing diabetes effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • T2DM diagnosis of less than 5 years
- • Age 18 to 80 years
- • Current residence in Nuevo León, México
- • Availability to attend in-person sessions
- • Provides written informed consent
- • Able to read and write
- Exclusion Criteria:
- • Currently under insulin treatment
- • T2DM diagnosis more than 5 years ago
- • Comorbidities such as active cancer, acquired immunodeficiency (HIV+, AIDS), liver, cardiovascular, renal, pulmonary or thyroid disease.
- • History of severe neurologic or psychiatric disease (current or past diagnosis)
- • Currently pregnant or intention of pregnancy in the following 3 months
- • Males that consume more than 4 alcoholic beverages daily or 14 weekly
- • Females that consume more than 3 alcoholic beverages daily or 7 weekly
- • Consumption of any illicit drug
About Tecsalud Investigación Clínica
Tecsalud Investigación Clínica is a leading clinical research organization dedicated to advancing medical science through innovative and ethical research practices. With a strong commitment to improving patient outcomes, Tecsalud specializes in conducting Phase I-IV clinical trials across various therapeutic areas. The organization collaborates with pharmaceutical and biotechnology companies to facilitate the development of new therapies, ensuring compliance with regulatory standards and upholding the highest quality in research. Through a multidisciplinary team of experienced professionals, Tecsalud strives to enhance the efficiency of clinical trials while prioritizing participant safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Pedro Garza Garcia, Nuevo León, Mexico
Santa Catarina, Nuevo León, Mexico
Patients applied
Trial Officials
Tania Zertuche, MD
Principal Investigator
Director de Instituto de Bienestar y Prevención
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported